Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(1.62) by 5.56 percent. This is a 13.33 percent decrease over losses of $(1.35) per share from the same period last year. The company reported quarterly sales of $34.11 million which beat the analyst consensus estimate of $29.24 million by 16.65 percent. This is a 33.82 percent decrease over sales of $51.53 million the same period last year.